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•	Most	 states	 implemented	 Medicaid	 cost	 containment	 measures	
between	2001	and	2005	to	control	 rising	pharmaceutical	costs;	
by	2009,	46	 states	had	 implemented	 a	prior	 authorization	 (PA)	
program,	 and	 45	 states	 had	 implemented	 a	 preferred	 drug	 list	
(PDL).	
•	Medicaid	 currently	 pays	 for	 greater	 than	 50%	 of	 all	 publicly	
funded	behavioral	health	care	and	greater	than	25%	of	all	behav-
ioral	 health	 care	 nationwide.	 Previous	 studies	 have	 shown	 that	
managed	care	initiatives	reduce	expenditures	but	can	have	vari-
able	effects	on	health	care	utilization.
What is already known about this subject
Cost and Utilization of Behavioral Health Medications Associated 
with Rescission of an Exemption for Prior Authorization for Severe 
and Persistent Mental Illness in the Vermont Medicaid Program
Jason C. Simeone, PhD; Rita M. Marcoux, MBA, RPh; and Brian J. Quilliam, PhD, RPh
ABSTRACT
BACKGROUND: In recent years, many state Medicaid programs have 
implemented preferred drug lists (PDL) to control pharmaceutical costs 
by generating supplemental rebate revenues and directing providers to 
the most cost-effective treatments. Two states, Michigan and Vermont, 
sought approval from the Centers for Medicare & Medicaid Services for 
supplemental rebates for their Medicaid fee-for-service programs in 2002. 
Behavioral health medications were largely excluded from PDLs and other 
managed care initiatives implemented by state Medicaid programs because 
of significant opposition to any impact on this “vulnerable” population. In 
November 2001, the Vermont Medicaid program implemented the Vermont 
Health Access Pharmacy Benefit Management Program, a PDL designed to 
promote cost-effective use of medications. Despite the potential cost sav-
ings resulting from implementation of a PDL, behavioral health providers 
and advocates in the state of Vermont opposed the implementation of the 
managed care initiative for beneficiaries with severe mental illness, and 
after January of 2002, Vermont’s program was changed to exempt benefi-
ciaries meeting the “severe and persistent mental illness” (SPMI) criteria 
from prior authorization (PA) for behavioral health medications not on the 
Medicaid PDL. The SPMI exemption was phased out by June 30, 2006.
OBJECTIVES: To determine the effects of the rescission of the PA exemp-
tion on utilization and costs of 3 classes of behavioral health medications 
(antidepressants, antipsychotics, and anxiolytics/sedatives). Secondary 
analyses were conducted to assess the association between rescission of 
the PA exemption and 2 quality measures that might be associated with 
pharmacy management policy: (a) behavioral health hospitalizations and  
(b) high-dose prescribing of antipsychotics, defined as dosing that exceed-
ed the manufacturer-recommended maximum dose by 25%. 
METHODS: This was a retrospective analysis of pharmacy claims for 
beneficiaries of the Office of Vermont Health Access Medicaid Program 
for dates of service from July 1, 2005, through December 31, 2007. The 
12-month PA exemption period for 3 categories of drugs (antidepressants, 
antipsychotics, and anxiolytics/sedatives) was July 1, 2005, through June 
30, 2006; and the post-PA exemption period was the 12 months from 
January 1, 2007, through December 31, 2007, following rescission of the 
SPMI exemption. Costs in this analysis were defined as the amount paid 
by Medicaid, excluding federal drug rebates paid by drug manufacturers 
and supplemental rebates associated with the PDL program. Costs were 
adjusted for inflation using the Consumer Price Index for medical costs. 
Frequencies were used to identify trends between medication classes and 
time periods. Medical claims from the 2 time periods were used to assess 
inpatient hospitalization trends. Descriptive statistics, Pearson chi-square 
tests (for categorical data), and t-tests (for continuous data) were used to 
assess the 2 study cohorts.
RESULTS: 17.8% (n=22,130) of 124,169 eligible beneficiaries in the PA 
exemption period had 1 or more pharmacy claims in the 3 classes of 
RESEARCH
medications exempt from PA versus 19.2% (n=23,717) of 123,499 eligible 
beneficiaries in the post-PA exemption period. Utilization of behavioral 
medications per member per month (PMPM) increased by 14.3% from 
0.14 claims PMPM in the PA exemption period to 0.16 claims PMPM in the 
post-PA exemption period, similar to the 14.1% increase in the utilization 
of nonbehavioral medications (from 0.64 to 0.73 claims PMPM). Utilization 
changed little between the PA exemption period and the post-PA exemp-
tion period for the 3 individual classes of behavioral health drugs, 0.08 
claims PMPM versus 0.09 claims PMPM for antidepressants and 0.03 for 
both study periods for both antipsychotics and anxiolytics/sedative hyp-
notics. PMPM costs for the 3 drug classes exempt from PA increased by 
2.1% from $12.76 to $13.03, compared with a 12.2% increase from $42.58 
PMPM to $47.79 PMPM for nonbehavioral health medications. The small 
2.1% increase in PMPM costs for the 3 formerly PA-exempt drug classes 
was attributable in part to a 12.9% reduction in average cost per pharmacy 
claim, from $94.05 to $81.92, including a 24.8% reduction in the average 
cost per antidepressant claim, from $65.59 to $49.33. For the subgroup 
of beneficiaries taking atypical antipsychotic medications, the percentage 
with high-dose prescriptions decreased from 3.1% to 2.2%. Mental health 
inpatient hospitalizations also decreased from 0.6% of beneficiaries in the 
PA exemption period to 0.4% in the post-PA exemption period. 
CONCLUSIONS: In a Medicaid population excluding Medicare dual-eligible 
beneficiaries, the rescission of a PA exemption for 3 major classes of 
behavioral health medications in a PDL was not associated with decreased 
utilization of formerly PA-exempt behavioral health medications. The 
increase in PMPM spending for the formerly PA-exempt behavioral health 
medications was small compared with the increase in PMPM cost for non-
behavioral health medications, and there were fewer beneficiaries with 
hospitalization for mental health reasons in the period after rescission of 
the PA exemption.
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physicians	 are	 permitted	 to	 prescribe	 all	 medications,	 “pre-
ferred”	 medications	 do	 not	 require	 PA	 when	 the	 pharmacy	
claim	is	submitted.
In	 the	 late	 1990’s,	 behavioral	 health	 medications	 were	
largely	 excluded	 from	 PDLs	 and	 managed	 care	 initiatives	
implemented	 by	 state	 Medicaid	 fee-for-service	 programs	 out	
of	 concern	 for	 the	 “vulnerability”	 of	 the	 beneficiaries	 taking	
these	 medications.6	 This	 exclusion	 from	 managed	 care	 and	
care	management	initiatives	occurred	at	a	time	when	spending	
on	 behavioral	 health	 medications	 represented	 approximately	
20%	of	all	Medicaid	drug	expenditures.7	Increased	utilization	
is	 likely	 a	 result	 of	 several	 factors;	 newer	 medications	 may	
have	 fewer	 side	 effects,	 and	 there	has	been	a	decrease	 in	 the	
stigmatization	 of	 individuals	 taking	 behavioral	 medications.	
In	 addition,	 antidepressants,	 antipsychotics,	 and	 anxiolytics	
are	increasingly	being	prescribed	for	off-label	uses.8	American	
pharmaceutical	manufacturers	are	developing	at	least	300	new	
medications	designed	to	treat	the	nearly	60	million	Americans	
suffering	 from	 behavioral	 disorders.9	 Although	 the	 develop-
ment	of	so	many	new	medications	to	treat	behavioral	disorders	
is	 promising,	 states	 must	 still	 ensure	 that	 behavioral	 health	
programs	are	meeting	the	needs	of	their	beneficiaries	in	a	fis-
cally	responsible	manner.	
The	 State	 of	 Vermont’s	 Medicaid	 program	 is	 managed	 by	
the	 Office	 of	 Vermont	 Health	 Access	 (OVHA),	 and	 OVHA	
programs	cover	approximately	175,000	beneficiaries.	 In	early	
2000,	 government	 officials	 in	 Vermont	 were	 under	 constant	
pressure	 to	 control	 increasing	 drug	 expenditures	 without	
reducing	 services.10	 In	 2002,	 the	 General	 Assembly	 adopted	
legislation	 authorizing	 a	 prescription	 drug	 cost	 containment	
program	that	included	the	implementation	of	a	PDL	and	a	PA	
program	 for	nonpreferred	drugs.11-12	A	number	of	 constituent	
groups	 in	 the	mental	 health	 advocacy	 community,	 including	
caregivers	 and	 physicians,	 supported	 an	 exemption	 from	 PA	
for	behavioral	health	medications	in	the	PDL.13	In	response	to	
their	 concerns,	 the	 Vermont	 legislature	 exempted	 beneficia-
ries	identified	as	having	“severe	and	persistent	mental	illness”	
(SPMI)	 from	PA	 for	 any	medication	 being	 used	 to	 treat	 their	
behavioral	 health	 illness	 regardless	 of	 the	 positioning	 of	 the	
medication	on	the	PDL.14	The	SPMI	designation	was	defined	in	
2002	by	the	following	criteria:14 
•	 Patient	diagnosed	with	schizophrenia	or	bipolar	disorder.
•	 Patient	 diagnosed	 with	 an	 International Classification of 
Diseases, Ninth Revision, Clinical Modification	 (ICD-9-CM)	
diagnosis	code	for	mental	health	or	substance	abuse	(includ-
ing	major	depression,	290.00	-	319.00)	and	has	or	has	had	a	
history	of	 impairment	due	to	 the	mental	 illness	 that	affects	
his/her	 ability	 to	 function	 such	 that	 the	patient	 is	 suicidal,	
has	 no	 friends,	 neglects	 family,	 is	 unable	 to	 work	 or	 keep	
a	 job,	 is	withdrawn	 to	home	or	 room,	stays	 in	bed	all	day,	
becomes	 violent,	 or	 has	 even	 lesser	 degrees	 of	 functioning	
(Global	Assessment	of	Functioning	Scale	score	of	50	or	less).
Implementation	 of	 the	 Medicare	 Part	 D	 drug	 benefit	 on	January	1,	2006,	shifted	about	one-half	of	Medicaid	spending	(for	dual-eligible	beneficiaries)	to	the	Medicare	program,	but	
states	continued	to	seek	control	of	rising	pharmaceutical	costs	
using	tools	such	as	preferred	drug	lists	(PDLs),	prior	authoriza-
tion	(PA),	and	supplemental	rebate	programs	that	were	initiated	
between	2001	and	2005.1	By	2009,	45	state	Medicaid	programs	
had	 a	 PDL,	 and	 46	 states	 had	 PA	 requirements	 for	 pharma-
ceuticals.	 Increases	 in	 Medicaid	 spending	 per	 beneficiary	
declined	from	14.0%	in	2000-2002	to	0.7%	in	2005-2007,	after	
adjustment	 for	 the	 shift	 of	 costs	 to	Medicare	 for	 dual-eligible	
beneficiaries.2	 Prescription	drug	 trends	 are	driven	by	 a	num-
ber	 of	 factors	 including	 price	 increases,	 utilization,	 mix,	 the	
introduction	of	new	products,	pharmaceutical	advertising,	and	
the	increasing	number	of	biotechnology	products	used	to	treat	
chronic	conditions.3	Fiscal	constraints	are	requiring	Medicaid	
officials	 to	 seek	 innovative	 approaches	 to	 delivering	 quality	
health	 care	 to	 an	 increasing	 number	 of	 individuals	 requiring	
care	for	complex	and	chronic	health	conditions.	
According	to	the	Centers	for	Medicare	&	Medicaid	Services	
(CMS),	33.4	million	beneficiaries	or	approximately	71%	of	the	
national	Medicaid	population	were	enrolled	in	a	managed	care	
program by 2008.4	 Every	 state	 except	 Alaska	 and	Wyoming	
has	 all,	 or	 a	 portion,	 of	 its	 Medicaid	 population	 enrolled	 in	
some	form	of	managed	care.1	Managed	Medicaid	organizations	
generate	rebates	that	do	not	benefit	 from	the	best	price	man-
dates	of	the	Omnibus	Budget	Reconciliation	Act	(OBRA)	rebate	
program	administered	by	CMS.	While	states	do	share	in	OBRA	
rebates	with	 the	 federal	 government,	 a	 few	 states	 challenged	
CMS	to	allow	them	to	work	with	pharmaceutical	manufactur-
ers	to	increase	their	rebate	revenue	by	entering	into	supplemen-
tal	rebate	agreements	based	on	the	implementation	of	PDLs	in	
their	 states.1,5	Manufacturers	 agreed	 to	pay	 additional	 rebates	
for	 preferred	 placement	 on	 the	 Medicaid	 PDLs.	 Although	 
•	After	 rescission	 of	 a	 PA	 exemption	 and	 implementation	 of	 a	
behavioral	health	PA	requirement	in	the	Vermont	Medicaid	pro-
gram,	per	member	per	month	pharmaceutical	costs	for	behavioral	
health	medications	 increased	 by	 2.1%	 compared	with	 a	 12.2%	
increase	for	all	nonbehavioral	health	medications,	and	utilization	
of	the	formerly	PA-exempt	behavioral	health	medications	did	not	
decrease.	
•	Preliminary	 results	 indicate	 that	 implementation	 of	 a	 PDL	 and	
corresponding	PA	program	for	a	mental	health	subgroup	of	 the	
Medicaid	 population	 were	 not	 associated	 with	 an	 increase	 in	
inpatient	 mental	 health	 hospitalizations,	 and	 use	 of	 high-dose	
antipsychotics	 (meeting	 the	 threshold	 for	 PA)	 decreased	 from	
3.1%	to	2.2%	of	beneficiaries.
What this study adds
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pharmacy	claims	processing	 system	until	 June	2006	because	
of	the	major	changes	that	took	place	with	eligibility	associated	
with	implementation	of	the	Medicare	Part	D	benefit	beginning	
in	January	2006.	
We	 conducted	 a	 retrospective	 study	 of	 PA	 exemption	
and	 post-PA	 exemption	 cohorts	 to	 assess	 the	 association	 of	
Vermont’s	implementation	of	a	PDL	and	PA	program	for	behav-
ioral	health	medications	with	health	care	utilization	and	costs.	
We	evaluated	(a)	behavioral	health	medication	utilization	and	
drug	costs	in	3	of	the	major	drug	classes,	and	(b)	2	measures	
that	might	capture	some	of	the	possible	adverse	consequences	
of	drug	use	restrictions:	use	of	high-dose	antipsychotic	agents	
and	mental	health	hospitalizations	before	and	after	the	rescis-
sion	of	the	SPMI	exemption.
■■  Methods
We	 conducted	 a	 nonconcurrent	 retrospective	 cohort	 study,	
evaluating	2	 time	periods	 in	relation	 to	OVHA’s	rescission	of	
the	 SPMI	 exemption.	 The	 first	 time	 period	 for	 this	 analysis,	
July	1,	2005	to	June	30,	2006,	represented	the	final	12-month	
period	 during	 which	 beneficiaries	 who	 were	 designated	 as	
SPMI	were	exempt	from	PDL	and	PA	requirements	for	behav-
ioral	health	medications,	hereafter	referred	to	as	the	PA	exemp-
tion	period.	We	 identified	 a	 second	12-month	period	during	
which	the	PDL	and	PA	programs	were	fully	implemented	from	
January	1,	 2007	 through	December	 31,	 2007,	 as	 the	post-PA	
exemption	period.	Our	selection	of	these	time	periods	allowed	
for	 a	 6-month	 wash-out	 period	 after	 rescission	 of	 the	 SPMI	
exemption.	 For	 each	 of	 these	 time	 periods,	 we	 included	 all	
beneficiaries	with	continuous	enrollment	during	the	 interval.	
From	these	eligible	populations,	we	then	excluded:	(a)	persons	
eligible	 for	Medicare	Part	D	 including	dual	eligibles	 (because	
Medicare	 became	 the	 primary	 payer	 for	 pharmaceuticals	
beginning	in	January	2006,	and	the	OVHA	as	secondary	payer	
did	not	 apply	 the	 PDL	 and	PA	program	 to	 these	 claims);	 (b)	
beneficiaries	who	qualified	 for	pharmaceutical	 aid	 from	state	
programs	 other	 than	 Medicaid;	 and	 (c)	 beneficiaries	 being	
treated	 for	hemophilia	and	Hunter’s	 syndrome	(because	high	
costs	 for	 associated	 pharmaceutical	 agents	 would	 skew	 the	
cost	 analyses).	 After	 the	 exclusion	 of	 beneficiaries,	 124,169	
Medicaid	 beneficiaries	 qualified	 during	 the	 PA-exemption	
period	(Figure	1),	and	123,449	beneficiaries	qualified	for	inclu-
sion	in	the	post-PA	exemption	period	(Figure	2).
Simple	descriptive	statistics	were	used	to	describe	the	char-
acteristics	of	the	populations	in	both	study	periods.	Descriptive	
statistics	 included	 means	 and	 standard	 deviations	 (for	 con-
tinuous	 covariates)	 and	 frequencies	 (for	 categorical	 variables	
of	interest).	We	compared	the	2	time	periods	for	differences	in	
demographic	 characteristics	 including	 age,	 gender,	 and	 race/
ethnicity	using	data	collected	by	OVHA	and	contained	in	the	
Vermont	Medicaid	eligibility	files.
•	 Patient	 is	 a	 past	 or	 current	 user	 of	 traditional	 or	 atypical	
antipsychotic	medication.
•	 Patient	 has	 received	 chronic	 therapy	with	 any	 antidepres-
sant	medication	(received	at	least	300	days	supply	of	medi-
cation	during	a	365	day	period).
•	 Patient	has	 received	chronic	 therapy	with	any	central	ner-
vous	 system	 stimulant	 medication	 (received	 at	 least	 240	
days	supply	of	medication	during	a	365	day	period).
•	 Presence	 of	 a	 Community	 Rehabilitation	 and	 Treatment	
(CRT)	code	in	eligibility	file.
•	 Patient	less	than	18	years	of	age.
SPMI	exemption	was	determined	on	each	pharmacy	claim;	
therefore	 an	 overall	 marker	 of	 the	 SPMI	 exemption	 was	 not	
a	 part	 of	 a	 beneficiary’s	 eligibility	 file,	 and	 exemption	 was	
determined	 each	 time	 the	 beneficiary	 presented	 a	 new	 pre-
scription	 for	 a	 behavioral	 health	 medication.	 Furthermore,	
the	 policy	 stipulated	 that	 a	 beneficiary	 found	 to	 be	 exempt	
for	 any	 reason	 other	 than	 age	would	 remain	 exempt	 as	 long	
as	he	or	she	continued	to	meet	at	least	1	of	the	SPMI	exemp-
tion	criteria.14	This	 inclusive	 exemption	policy	gave	prescrib-
ers	 continued	 flexibility	 in	managing	 the	 care	 of	 these	 SPMI	
beneficiaries	 while	 allowing	 the	 OVHA	 the	 ability	 to	 imple-
ment	the	new	PDL	and	PA	policy	to	ensure	fiscal	and	clinical	
responsibility	 of	 the	 overall	 program.	 A	 new	 initiative	 was	
added	as	part	of	the	PA	policy	that	monitored	the	use	of	high-
dose	 prescribing	 of	 behavioral	 health	 medications	 to	 ensure	
that	 patients	 did	 not	 continue	 to	 receive	 high-dose	 therapy	
that	 offered	 limited	 or	 no	 clinical	 benefit.	 The	 program	 and	
its	 PDL	 were	 authorized	 by	 the	 state	 legislature	 in	 2002	 for	
implementation	in	the	state	fiscal	year	ending	June	30,	2002.14 
Both	 current	 and	historical	OVHA	PDLs	 are	 available	 online	
on	 the	OVHA	website	 (http://ovha.vermont.gov/for-providers/ 
preferred-drug-list-clinical-criteria).	 The	 SPMI	 exemption	 to	
the	PDL	and	PA	program	was	scheduled	to	end	July	1,	2004,	
but	 was	 extended	 through	 June	 30,	 2006.	 In	 response	 to	
concerns	from	the	health	care	community	and	caregivers,	the	
OVHA	permitted	beneficiaries	using	nonpreferred	medications	
prior	 to	 the	 exemption	 rescission	 to	 be	 “grandfathered”	 to	
prevent	 “destabilization”	 of	 therapy.	However,	 lapses	 in	 drug	
therapy	of	4	months	or	longer	resulted	in	the	application	of	the	
PDL	for	these	beneficiaries.14
The	 utilization	 and	 cost	 of	 these	 behavioral	 health	medi-
cations	 continued	 to	 escalate	 and	 remained	 in	 the	 top	 thera-
peutic	 classes	 by	 expenditure	 in	 the	 state	Medicaid	 program	
through	 2005.	 The	 2006	 Budget	 Act	 passed	 by	 the	 Vermont	
legislature	had	provisions	to	allow	the	inclusion	of	behavioral	
health	drugs	on	the	PDL.14	In	2006,	the	OVHA	revised	its	PDL	
and	PA	program	to	 include	 the	previously	exempt	behavioral	
health	 classes	 of	 medications,	 and	 SPMI	 patients	 were	 then	
subject	 to	 the	PDL	program	requirements.14	The	phase-out	of	
the	PA	exemption	was	not	implemented	in	a	“hard	edit”	in	the	 
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The	next	phase	of	these	analyses	entailed	estimating	the	preva-
lence	 of	 behavioral	 medication	 use	 and	 the	 associated	 costs	
to	 the	Medicaid	program.	For	our	 analyses,	we	 focused	on	3	
distinct	classes	of	medications	that	were	included	in	the	SPMI	
exemption:	 antidepressants,	 antipsychotics,	 and	 anxiolytics/
sedative	hypnotics.	The	OVHA	uses	the	First	DataBank	(First	
DataBank,	San	Francisco,	CA)	Specific	Therapeutic	Class	(STC)	
codes	to	identify	drug	classes.	To	identify	medications	of	inter-
est,	we	used	STC	codes	to	identify	claims	among	eligible	ben-
eficiaries	 for	 antidepressants	 (e.g.,	 duloxetine,	 sertraline,	 and	
amitriptyline),	 antipsychotics	 (e.g.,	 aripiprazole,	 haloperidol)	
and	 anxiolytics/sedative	 hypnotics	 (i.e.,	 anti-anxiety	 medica-
tions	such	as	alprazolam;	and	barbiturate	and	nonbarbiturate	
sedative-hypnotics	such	as	zolpidem).	After	preliminary	iden-
tification	of	pharmacy	claims	using	these	STC	codes,	we	also	
completed	a	text-string	search	to	verify	the	medications	listed	
in	 each	 class	 identified	during	 the	preliminary	 classification.	
We	 estimated	 utilization	 rates	 for	 overall	 behavioral	 health	
medication	 at	 the	 beneficiary	 level	 where	 the	 denominator	
included	 the	 total	 number	 of	 eligible	 beneficiaries	 within	
each	 cohort	 and	 the	 numerator	 included	 the	 total	 number	
of	 beneficiaries	 utilizing	 at	 least	 1	 behavioral	 health	 medi-
cation	 (antidepressant,	 antipsychotic,	 or	 anxiolytic/sedative	
hypnotic).	 Similar	 calculations	were	 completed	 for	 each	 indi-
vidual	 drug	 class,	 including	 antidepressants,	 antipsychotics,	
and	 anxiolytics/sedative	 hypnotics.	 Differences	 in	 the	 use	 of	 
behavioral	health	medications	overall	and	by	 individual	class	
were	 compared	 between	 the	 2	 cohorts	 by	 frequencies	 and	
Pearson	chi-square	testing.	
Because	 part	 of	 the	 PDL	 initiative	 focused	 on	 excessive	
dosing	 of	 antipsychotics,	 we	 further	 evaluated	 differences	 in	
the	prescription	of	 antipsychotic	medications	above	 the	daily	
dose	 requiring	 PA	 (according	 to	 OVHA)	 across	 the	 2	 study	
periods.	Utilizing	National	Drug	Codes	 (NDC),	we	 identified	
the	 strength	 of	 the	 antipsychotic	 medication	 dispensed	 and	
calculated	the	average	daily	dose	using	the	number	of	units	dis-
pensed	and	days	supply	reported	in	pharmacy	claims	(average	
daily	dose	=	[strength	X	units]	÷	days	supply).	We	then	dichoto-
mized	this	dose	as	above	or	below	125%	of	the	manufacturer’s	
maximum	daily	dose,	as	specified	in	OVHA	“dosage	guidelines	
for	 PA”	 (aripiprazole	 ≥	40	milligrams	 [mg];	 clozapine	 ≥	1,125	
mg;	 olanzapine	 ≥	50	mg;	 quietapine	 ≥	1,000	mg;	 risperidone	
≥	10	mg;	and	ziprasidone	≥	200	mg)14	and	compared	this	quan-
tity	between	the	2	cohorts	using	Pearson	chi-square	analysis.
To	compare	costs	for	behavioral	health	medications	in	each	
of	the	cohorts,	we	analyzed	costs	paid	by	the	Vermont	Medicaid	
program	(not	including	manufacturer	rebates	from	federal	pay-
ments	 and	 supplemental	 rebates)	 after	 adjusting	 for	 inflation	
utilizing	methods	developed	by	the	Bureau	of	Labor	Statistics.15 
All	costs	were	adjusted	for	inflation	according	to	the	December	
2007	 Consumer	 Price	 Index	 (CPI)	 for	 medical	 costs	 in	 the	
Boston-Brockton-Nashua	 area	 (December,	 2007	 CPI	=	489.8),	
which	was	the	closest	available	geographical	area	to	Vermont.	
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OVHA = Office of Vermont Health Access; PA = prior authorization.
Vermont Medicaid beneficiaries enrolled from  
July 1, 2005, through June 30, 2006
n = 182,653
FIGURE 1 Selection of Beneficiaries for PA Exemption Cohort
Beneficiaries excluded for dual eligibility in  
Medicaid and Medicare
n = 38,253 (20.9%)
Beneficiaries enrolled only in Medicaid
n = 144,400
Beneficiaries excluded for enrollment in other  
OVHA programs
n = 20,228
Beneficiaries with claims paid only by Medicaid
n = 124,172
Beneficiaries excluded with hemophilia (n = 3)
Beneficiaries excluded with Hunter’s Syndrome (n = 0)
Eligible PA exemption cohort
n = 124,169
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For	each	month	during	the	study	period,	we	identified	the	CPI	
for	 medical	 care	 costs	 in	 the	 Boston-Brockton-Nashua	 Area	
(e.g.,	CPI	=	456.7	for	June	2006).	We	then	determined	the	per-
cent	inflation	by	dividing	the	CPI	for	December,	2007	by	the	
CPI	for	each	month	during	the	study	period.	Costs	within	each	
month	were	 then	multiplied	by	 this	 factor	 to	adjust	 the	costs	
for	 inflation.	Within	 each	 cohort,	we	 calculated	per	member	
per	 month	 (PMPM)	 costs	 for	 all	 pharmaceuticals	 (includ-
ing	 behavioral	 health	medications),	 for	 nonbehavioral	 health	
medications,	for	behavioral	health	medications	overall,	and	for	
each	of	the	3	classes	of	behavioral	health	medications.	We	then	
compared	costs	across	the	2	cohorts	utilizing	t-tests.	
Behavioral Health Hospitalizations
Finally,	as	shifts	in	drug	utilization	patterns	may	affect	behav-
ioral	health	hospitalizations,	we	assessed	rates	of	hospitaliza-
tion	between	the	2	cohorts.	We	 identified	all	hospitalizations	
for	each	study	period	where	a	mental	health	disorder	(bipolar	
disorder,	 depression,	 schizophrenia,	 personality	 disorders,	
anxiety	disorders,	 and	other	mental	health	disorders	 such	 as	
delusional	 disorders	 and	 pervasive	 developmental	 disorders)	
was	listed	as	the	principal	diagnosis	on	the	facility	claim	(Table	
1).	 Inpatient	 hospitalizations	 were	 identified	 using	 a	 unique	
claim	 type	 code	 present	 in	 the	 Vermont	 Medicaid	 database.	
The	claim	type	code	for	inpatient	claims	includes	hospitaliza-
tions	 at	 general	 hospitals,	 freestanding	 psychiatric	 hospitals,	
and	 state	 mental	 health	 hospitals.	 We	 then	 compared	 the	 
proportions	 of	 inpatient	 hospitalizations	 from	 each	 study	
period	using	Pearson	chi-square	testing.	
All	 statistical	 tests	 were	 performed	 using	 an	 a	 priori	
Cost and Utilization of Behavioral Health Medications Associated with Rescission of an  
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Primary 
Hospitalization 
Diagnosis ICD-9-CM Codes 
Depression 296.2,	296.3,	298.0,	300.4,	309.0,	309.1
Schizophrenia 295.0-295.9
Bipolar	disorder 296.0, 296.1, 296.4-296.8
Personality	disorder 301.xx	except	301.21
Anxiety	disorder 300.0-300.02,	300.11,	300.21-300.23,	300.3,	
300.7,	300.81,	300.82,	309.81
Other	mental	health	
disorders
297.0-297.9, 298.2-298.4, 298.9, 299.0-299.9, 
300.10,	300.5,	300.6,	300.8,	302.0-302.9,	306.0-
307.9,	308.0-308.9,	309.22,	309.23,	309.29,	
309.82,	309.83,	310.0-310.9,	312.0-316.9
Drug Classes Drug Class Codesa
Antipsychotics H2G,	H2L,	H7O,	H7P,	H7R,	H7S,	H7T,	H7U,	H7X,	
H7Z
Antidepressants H2J,	H2K,	H2S,	H2U,	H2W,	H2X,	H7B,	H7C,	
H7D,	H7E,	H7J
Anxiolytics/sedative	
hypnotics
H2D,	H2E,	H2F
aFirst DataBank Specific Therapeutic Class (STC) codes (First DataBank, San 
Francisco, CA).
ICD-9-CM = International Classification of Diseases, Ninth Revision, Clinical 
Modification.
TABLE 1 Hospitalization and Drug Class Codes
OVHA = Office of Vermont Health Access; PA = prior authorization.
Vermont Medicaid beneficiaries enrolled  
January 1, 2007, through December 31, 2007
n = 175,559
FIGURE 2 Selection of Beneficiaries for Post-PA Exemption Cohort
Beneficiaries excluded for dual eligibility in  
Medicaid and Medicare
n = 34,892 (19.9%)
Beneficiaries enrolled only in Medicaid
n = 140,667
Beneficiaries excluded for enrollment in other  
OVHA programs
n = 17,213
Beneficiaries with claims paid only by Medicaid
n = 123,454
Beneficiaries excluded with hemophilia (n = 4)
Beneficiaries excluded with Hunter’s Syndrome (n = 1)
Eligible post-PA exemption cohort
n = 123,449
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Variable
PA Exemption Cohort  
n = 124,169b
Post-PA Exemption Cohort 
n = 123,449c P Valued
Age
Mean	[SD]	and	t-test	P	value 20.4		[16.4] 21.2		[17.0] < 0.001
Age	ranges	in	years
%	(n)	Pearson	chi-square	P	value
Younger	than	18 	 54.9%	 (68,095) 	 53.0%	 (65,420)
< 0.001
18-34 	 24.6%	 (30,597) 	 24.9%	 (30,691)
35-64 	 20.2%	 (25,058) 	 21.8%	 (26,853)
65	or	older 	 0.3%	 (381) 	 0.4%	 (448)
Gender
%	(n)	Pearson	chi-square	P	value
Female 	 53.8%	 (66,726) 	 53.8%	 (66,341)
0.995
Male 	 46.2%	 (57,405) 	 46.2%	 (57,071)
Race
%	(n)	Pearson	chi-square	P	value
Black 	 1.2%	 (1,532) 	 1.3%	 (1,577)
0.067
White 	 55.6%	 (68,993) 	 55.4%	 (68,316)
Other 	 0.8%	 (997) 	 0.9%	 (1,109)
Not	known/not	reported 	 42.4%	 (52,609) 	 42.5%	 (52,410)
aPercentages may not total 100% due to rounding. The PA exemption period was the 12 months between July 1, 2005, and June 30, 2006; the post-PA exemption period 
was the 12 months between January 1, 2007, and December 31, 2007.
b38 beneficiaries were missing demographic information in the PA exemption cohort.
c37 beneficiaries were missing demographic information in the post-PA exemption cohort.
dT-test for the comparison of mean age and Pearson chi-square for the other characteristics.
PA = prior authorization; SD = standard deviation. 
TABLE 2 Demographic Characteristics of All Vermont Medicaid Beneficiaries 
Eligible for Study Inclusion Stratified by Study Perioda
PA Exemption  
Cohorta 
n = 124,169
Post-PA Exemption 
Cohortb 
n = 123,449
Absolute 
Change
Percent  
Change (%)
Pearson  
Chi-Square P Value
%	utilizing	beneficiaries	(n)
Antidepressants 	 14.4%	 (17,872) 	 15.4%	 (18,968) 1.0 6.9 46.16 < 0.001
SSRI 	 10.2%	 (12,694) 	 11.1%	 (13,697) 0.9 8.8
53.09 < 0.001TCA 	 1.3%	 (1,588) 	 1.3%	 (1,580) 0.0 0.0
Otherc 	 2.9%	 (3,590) 	 3.0%	 (3,691) 0.1 3.4
Antipsychotics 	 3.6%	 (4,487) 	 3.8%	 (4,724) 0.2 5.6 7.85 0.005
Typical 	 0.5%	 (678) 	 0.6%	 (760) 0.1 20.0
9.51 0.009
Atypical 	 3.1%	 (3,809) 	 3.2%	 (3,964) 0.1 3.2
Anxiolytics/sedatives 	 6.4%	 (7,956) 	 7.5%	 (9,240) 1.1 17.2 111.21 < 0.001
Benzodiazepine 	 5.1%	 (6,366) 	 6.0%	 (7,407) 0.9 17.6
121.77 < 0.001Sleep	aid 	 1.2%	 (1,462) 	 1.4%	 (1,736) 0.2 16.7
Barbiturate 	 0.1%	 (128) 	 0.1%	 (97) 0.0 0.0
Any behavioral health medicationd 	 17.8%	 (22,130) 	 19.2%	 (23,717) 1.4 7.9 79.22 < 0.001
aThe PA exemption period was the 12 months between July 1, 2005, and June 30, 2006.
bThe post-PA exemption period was the 12 months between January 1, 2007, and December 31, 2007.
cOther antidepressants include MAOIs, NDRIs, SNRIs, and alpha-2 receptor antagonist antidepressants. 
dBeneficiaries in this row were counted once if they had at least 1 pharmacy claim for antidepressants, antipsychotics, or anxiolytics/sedatives.
MAOI = monoamine oxidase inhibitor; NDRI = norepinephrine and dopamine reuptake inhibitor; PA = prior authorization; SNRI = serotonin-norepinephrine reuptake 
inhibitor; SSRI = selective serotonin reuptake inhibitor; TCA = tricyclic antidepressant.
TABLE 3 Users of Behavioral Health Medications
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There	 were	 4,374	 beneficiaries	 who	 received	 1	 or	 more	
atypical	 antipsychotics	 in	 the	 PA	 exemption	 period	 versus	
4,586	beneficiaries	in	the	post-PA	exemption	period	(Table	4).	
The	proportion	of	beneficiaries	who	received	1	or	more	high-
dose	 atypical	 antipsychotics	 that	 would	 have	 required	 a	 PA	
(for	receipt	of	average	daily	dosing	greater	than	the	maximum	
established	by	OVHA)	decreased	from	3.1%	(n	=	134)	in	the	PA	
exemption	period	to	2.2%	(n	=	101)	in	the	period	after	discon-
tinuation	of	 the	PA	exemption	 (P =	0.011).	Among	 the	6	 indi-
vidual	atypical	antipsychotics,	 the	proportion	of	beneficiaries	
who	should	have	received	a	PA	for	high-dose	therapy	declined	
significantly	in	the	post-PA	exemption	period	for	aripiprazole,	
clozapine,	and	risperidone	(Table	4).	
Overall	 costs	 for	 pharmaceuticals	 increased	 from	 $82.5	
million	 in	 the	 12-month	 period	 from	 July	 1,	 2005,	 through	
June	30,	2006,	to	$90.1	million	in	the	12-month	period	from	
January	 1,	 2007,	 through	 December	 31,	 2007,	 or	 9.9%	 from	
$55.34	 to	$60.82	PMPM	 (Table	5).	The	 costs	 for	3	 classes	of	
behavioral	 health	medications	 increased	 by	 only	 2.1%	 in	 the	
post-PA	 exemption	 period	 compared	with	 the	 PA	 exemption	
period	(from	$12.76	to	$13.03	PMPM),	and	therefore	accounted	
for	 a	 smaller	 proportion	 of	 total	 pharmacy	 spending	 in	 the	
post-PA	 exemption	 period	 (21.4%)	 compared	 with	 the	 PA	
exemption	period	(23.1%).
The	 9.9%	 increase	 in	 PMPM	 spending	 for	 all	 drugs	 and	
the	 2.1%	 increase	 in	 PMPM	 spending	 for	 the	 3	 classes	 of	
behavioral	 health	 drugs	 were	 attributable	 to	 lower	 costs	 per	
pharmacy	claim	while	utilization	of	behavioral	health	medica-
tions	 increased	minimally.	 For	 all	 pharmaceuticals,	 the	 aver-
age	 cost	 per	 claim	 declined	 by	 4.0%	 from	 $71.04	 to	 $68.21	
(Table	 5).	 For	 the	 3	 classes	 of	 behavioral	 health	 drugs,	 the	 
average	 cost	 per	 claim	 declined	 by	 12.9%,	 from	 $94.05	 to	
2-tailed	alpha	 level	of	0.05,	and	all	analyses	were	performed	
using	 SAS	 statistical	 software	 (Version	 9.1.3,	 SAS	 Institute	
Inc.,	Cary,	NC).
■■  Results
The	 final	 study	 sample	 in	 the	 PA-exemption	 period	 (July	 1,	
2005,	 through	June	30,	2006)	was	124,169	(Figure	1).	 In	 the	
post-PA	 exemption	 period	 from	 January	 1,	 2007,	 through	
December	31,	2007,	123,449	beneficiaries	met	the	criteria	for	
study	 inclusion	 (Figure	 2).	 The	mean	 (SD)	 ages	 of	 Medicaid	
beneficiaries	 in	 this	 study	 were	 20.4	 (16.4)	 years	 in	 the	 PA	
exemption	period	and	21.2	(17.0)	years	in	the	post-PA	exemp-
tion	period	(Table	2).	The	study	population	was	predominantly	
younger	 than	 18	 years	 of	 age	 (54.9%	 PA	 exemption	 period,	
53.0%	 post-PA	 exemption	 period).	 Therefore,	 by	 definition,	
more	 than	 50%	 of	 the	 population	 during	 the	 PA	 exemption	
period	 qualified	 for	 the	 SPMI	 exemption	 by	 age	 alone.	 The	
majority	 of	 beneficiaries	 were	 female	 (53.8%	 of	 beneficiaries	
were	female	during	both	time	periods).	Race	and	ethnicity	were	
also	equally	distributed	in	the	2	periods;	however,	a	large	por-
tion	 of	 beneficiaries	 were	 missing	 race/ethnicity	 information	
during	both	study	periods	(>	42%).	
The	 use	 of	 any	 behavioral	 health	 medication	 rose	 from	
17.8%	 in	 the	 PA	 exemption	 period	 to	 19.2%	 in	 the	 post-PA	
exemption	period	(P <	0.001),	a	relative	increase	of	7.9%	(Table	
3).	Utilization	increased	for	each	of	the	3	sub-classes	of	behav-
ioral	health	medications	in	the	post-PA	exemption	period	com-
pared	with	the	period	in	which	the	PA	exemption	was	in	effect,	
from	3.6%	to	3.8%	of	beneficiaries	who	received	antipsychotics	
P =	0.005),	from	14.4%	to	15.4%	of	beneficiaries	who	received	
antidepressants	(P <	0.001),	and	from	6.4%	to	7.5%	of	beneficia-
ries	who	received	anxiolytics/sedative	hypnotics	(P <	0.001).	
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Medication
Daily Dose  
Requiring PA
PA Exemption Periodb Post-PA Exemption Periodc
Pearson  
Chi-Square P ValueSample Size
% (n) 
Exceeding Dose Sample Size
% (n) 
Exceeding Dose
All atypical antipsy-
chotics combinedd 
	 4,374 	 3.1%	(134)  4,586 	 2.2%	 (101)  6.50  0.011
Aripiprazole 	 ≥	40	mg  884 	 5.4%	 (48)	  880 	 3.4%	 (30)	  4.26 	 0.039
Clozapine 	 ≥	1,125	mg  84 	 8.3%	 (7)	  91 	 0.0%	 (0)  7.90  0.005
Olanzapine 	 ≥	50	mg 	 385 	 1.0%	 (4)	 	 325 	 1.2%	 (4)	  0.06  0.809
Quetiapine 	 ≥	1,000	mg  2,291 	 1.7%	 (39)	 	 2,330 	 1.6%	 (38)	  0.04  0.850
Risperidone 	 ≥	10	mg  1,478 	 1.7%	 (25)	  1,564 	 0.8%	 (13)	  4.56 	 0.033
Ziprasidone 	 ≥	200	mg  272 	 8.1%	 (22)	 	 343 	 5.8%	 (20)	  1.21  0.270
aThese are not counts of actual PA requests, but counts of patients with daily doses above the PA guideline set by the OVHA.14 Because patients could be on multiple  
antipsychotics during each of the 2 study periods, the estimates are shown at the the patient level.
bThe PA exemption period was the 12-month period from July 1, 2005, through June 30, 2006.
cThe post-PA exemption period was the 12-month period from January 1, 2007, through December 31, 2007.
dBecause a beneficiary may have received more than 1 atypical antipsychotic at high dose, the total sample size is the count of unique beneficiaries, not the sum of the  
beneficiary counts for the individual drugs.
mg = milligrams; OVHA = Office of Vermont Health Access; PA = prior authorization. 
TABLE 4 Beneficiaries Exceeding OVHA Atypical Antipsychotic Daily Dose Limitationsa
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health	 classes	 of	 drugs	 was	 relatively	 stable	 at	 0.14	 claims	
PMPM	in	the	PA	exemption	period	and	0.16	claims	PMPM	in	
the	post-PA	exemption	period,	including	essentially	no	change	
in	the	antidepressants,	from	0.08	claims	PMPM	to	0.09	claims	
PMPM,	and	no	change	in	the	antipsychotics	and	the	anxiolyt-
ics/sedative	hypnotics,	both	0.03	claims	PMPM	in	both	study	
periods	(Table	5).
Regardless	of	study	period,	antipsychotics	accounted	for	the	
largest	proportion	of	 spending	on	 the	3	classes	of	behavioral	
medications,	followed	by	antidepressants.	In	the	PA	exemption	
period,	antipsychotics	accounted	for	12.0%	of	total	pharmacy	
costs	 ($9,866,726	 of	 $82,469,957)	 and	 antidepressants	 for	
9.7%	 of	 total	 pharmacy	 costs	 ($7,984,246	 of	 $82,469,957).	
A	 similar	 percentage	 of	 overall	 pharmaceutical	 expendi-
tures	 were	 accounted	 for	 by	 these	medication	 classes	 in	 the	 
post-PA	 exemption	 period.	 After	 the	 PA	 exemption	 phase-
$81.92.	 The	 antidepressants	 accounted	 for	 most	 of	 the	 drop	
in	the	average	cost	per	claim	for	the	behavioral	health	drugs,	
declining	by	24.8%	from	$65.59	to	$49.33;	the	average	cost	per	
claim	for	the	antipsychotics	declined	by	4.0%	from	$235.56	to	
$226.10;	while	 the	average	cost	per	claim	for	 the	anxiolytics/
sedative	hypnotics	 increased	by	4.9%	from	$29.83	 to	$31.28.	
The	cost	per	claim	for	all	nonbehavioral	health	drugs	declined	
by	1.5%	from	$66.19	to	$65.23.
The	decline	in	the	average	cost	per	pharmacy	claim	helped	
suppress	 the	 effects	 of	 increased	 utilization	 in	 the	 post-PA	
exemption	period	for	all	drugs	including	the	behavioral	health	
drugs.	Spending	declined	by	13.8%	for	antidepressants	in	the	
post-PA	 exemption	 period	 (from	 $5.36	 to	 $4.62	 PMPM),	 but	
increased	 by	 11.1%	 for	 antipsychotics	 (from	 $6.64	 to	 $7.38	
PMPM)	 and	 by	 32.5%	 for	 the	 anxiolytics/sedative	 hypnotics	
(from	$0.77	 to	 $1.02	 PMPM).	Utilization	 of	 the	 3	 behavioral	
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PA Exemption Cohorta 
n = 124,169
Post-PA Exemption Cohortb 
n = 123,449 Absolute Change
Percent 
Change 
(%)c
T-test 
Statisticd P ValueTotale PMPM Totale PMPM Total PMPM
All medications
Claims 1,160,889 0.78 1,320,875 0.89 159,986 0.11 14.1
413.75 < 0.001Cost $82,469,957 $55.34 $90,093,724 $60.82 $7,623,767 $5.48 9.9
Cost	per	claim $71.04 $68.21 $2.83 -4.0
All nonbehavioral health medications
Claims 958,666 0.64 1,085,334 0.73 126,668 0.09 14.1
396.97 < 0.001Cost $63,450,118 $42.58 $70,797,124 $47.79 $7,347,006 $5.21 12.2
Cost	per	claim $66.19 $65.23 $0.96 -1.5
All behavioral health medicationsf
Claims 202,223 0.14 235,541 0.16 33,318 0.02 14.3
307.44 < 0.001Cost $19,019,839 $12.76 $19,296,601 $13.03 $276,762 $0.27 2.1
Cost	per	claim $94.05 $81.92 $12.13 -12.9
Antidepressants
Claims 121,737 0.08 138,837 0.09 17,100 0.01 12.5
341.84 < 0.001Cost $7,984,246 $5.36 $6,848,253 $4.62 $1,135,993 $0.74 -13.8
Cost	per	claim $65.59 $49.33 $16.26 -24.8
Antipsychotics
Claims 41,972 0.03 48,371 0.03 6,399 0.00 0.0
215.21 < 0.001Cost $9,886,726 $6.64 $10,936,675 $7.38 $1,049,949 $0.74 11.1
Cost	per	claim $235.56 $226.10 $9.46 -4.0
Anxiolytics/sedative hypnotics
Claims 38,514 0.03 48,333 0.03 9,819 0.00 0.0
134.02 < 0.001Cost $1,148,867 $0.77 $1,511,673 $1.02 $362,806 $0.25 32.5
Cost	per	claim $29.83 $31.28 $1.45 4.9
aThe PA exemption period was the 12 months between July 1, 2005, and June 30, 2006.
bThe post-PA exemption period was the 12 months between January 1, 2007, and December 31, 2007.
cFor the “claims” and “costs” rows, represents the percentage change in the PMPM value. For the “cost per claim” rows, represents the percentage change in the cost per 
claim.
dComparing the average PMPM cost in the 2 study cohorts.
eAll costs were adjusted for inflation according to the December 2007 CPI for medical costs in the Boston-Brockton-Nashua area (489.80), which was the closest available 
geographical area to Vermont. Costs from all months (except December 2007) were inflated to more appropriately compare costs during a period of high inflation for medi-
cal costs. Claims are pharmacy claims.
fBehavioral health medications defined as antidepressants, antipsychotics, and anxiolytics/sedative hypnotics.
CPI = Consumer Price Index; PA = prior authorization; PMPM = per member per month.
TABLE 5 Utilization and CPI-Adjusted Medication Costs
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that	 allowed	 certain	beneficiaries	with	 “severe	 and	persistent	
mental	 illness”	 to	 be	 exempt	 from	 the	 initiative.	 All	 covered	
beneficiaries	 in	 the	 state	 of	 Vermont	were	 subject	 to	 the	 use	
of	 a	 PDL	 after	 the	 SPMI	 exemption	 was	 phased	 out	 in	 June	
2006,	and	thus	if	the	implementation	of	the	PDL	was	effective,	
changes	 in	 utilization	 and	 costs	 should	 be	 evident	 follow-
ing	 the	 phase-out	 of	 the	 exemption.	Our	 study	 is	 important	
because	evaluation	of	public	programs	is	imperative	to	ensure	
that	health	care	 initiatives	maintain	quality	while	being	cost-
effective	and	use	available	resources	efficiently.
Since	 a	 large	 portion	 of	 the	 population	 qualified	 for	 
exemption	from	the	implementation	of	the	PDL,	it	 is	not	sur-
prising	that	costs	for	behavioral	health	medications	continued	
to	 escalate	 after	 implementation	 of	 the	 PDL.	 However,	 our	
analysis	shows	only	a	modest	2%	increase	in	PMPM	costs	for	
behavioral	 health	 medications,	 while	 PMPM	 costs	 increased	
12%	for	all	other	pharmaceuticals	 following	 the	phase-out	of	
the	 PA	 exemption.	 This	 suggests	 that	 the	 implementation	 of	
a	 PDL	with	 a	 corresponding	 PA	 process	may	 be	 an	 effective	
tool	 for	 managing	 cost	 increases	 without	 adversely	 affecting	
utilization	of	target	drugs	in	a	publicly	funded	pharmaceutical	
assistance	program.	Equally	important	was	the	relatively	stable	
utilization	of	behavioral	health	medications	between	the	2	time	
periods,	indicating	that	the	implementation	of	the	PDL	may	be	
shifting	 prescribing	 towards	 more	 cost-effective	 medications	
while	 not	 deterring	 medication	 prescribing	 as	 warranted	 for	
mental	health	conditions.	
Our	 analyses	 also	 indicated	 that	 hospitalizations	 and	
high-dose	 prescriptions	 of	 antipsychotic	medications	 did	 not	
increase	in	the	period	after	elimination	of	the	PA	exemption	for	
out,	 the	 cost	 of	 antipsychotics	 increased	 by	 approximately	
$1,050,000,	and	the	cost	of	anxiolytics/sedatives	 increased	 in	
this	 time	 period	 by	 approximately	 $363,000.	 However,	 dur-
ing	this	time	period,	the	cost	of	antidepressants	decreased	by	
approximately	$1,136,000.	Spending	on	all	medications	other	
than	 behavioral	 health	 medications	 rose	 by	 approximately	
$7.35	 million,	 and	 total	 pharmaceutical	 spending	 rose	 by	
approximately	$7.62	million	(9.2%)	 in	 the	post-PA	exemption	
period	compared	with	the	PA	exemption	period.	
Results	of	 the	analyses	of	 inpatient	hospitalizations	attrib-
utable	 to	 behavioral	 health	 disorders	 are	 presented	 in	 Table	
6.	Overall,	 during	 the	 PA-exemption	 period,	 there	were	 491	
(44.7%)	 fewer	mental	 health	 inpatient	 hospitalizations	 in	 the	
post-PA	 exemption	 period	 (n	=	608)	 compared	 with	 the	 PA	
exemption	period	(n	=	1,099).	The	unique	count	of	beneficiaries	
with	any	mental	health	hospitalization	(at	 least	1	hospitaliza-
tion	for	depression,	schizophrenia,	bipolar	disorder,	personal-
ity	disorder,	or	other	mental	health	disorders)	decreased	from	
0.64%	 (n	=	799)	 to	 0.37%	 (n	=	461;	 P <	0.001).	 The	 rates	 of	
hospitalization	for	5	of	the	6	specific	mental	health	diagnostic	
categories	were	significantly	lower	in	the	period	after	removal	
of	 the	 PA	 exemption	 compared	 with	 the	 period	 of	 the	 PA	
exemption	(Table	6).	
■■  Discussion
We	 conducted	 a	 retrospective	 cohort	 study	 to	 quantify	 the	
effect	 of	 a	 managed	 care	 initiative	 to	 promote	 the	 cost-
effective	 utilization	 of	 behavioral	 health	 medications	 and	
services.	Rather	than	directly	evaluating	the	effect	of	program	 
implementation,	we	focused	on	the	phase-out	of	an	exemption	
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PA Exemption Cohorta 
n = 124,169
Post-PA Exemption Cohortb 
n = 123,449
Absolute 
Changec
Percent 
Change 
(%)c
Pearson  
Chi- 
Squarec P Valuec
Total Number of 
Hospitalizations
Percent of 
Beneficiaries 
with at Least 1 
Hospitalization (n)
Total Number of 
Hospitalizations
Percent of 
Beneficiaries 
with at Least 1 
Hospitalization (n)
Any	mental	health	
hospitalizationd
1,099 	 0.64%	 (799) 608 	 0.37%	 (461) 0.27 -42.2 89.17 <0.001
Depression 459 	 0.29%	 (359) 221 	 0.15%	 (181) 0.14 -48.3 57.77 <0.001
Schizophrenia 99 	 0.05%	 (65) 60 	 0.04%	 (44) 0.01 -20.0 3.93	 0.048
Bipolar	disorder 155 	 0.11%	 (137) 95 	 0.06%	 (78) 0.05 -45.5 15.86 <0.001
Personality	disorder 23 	 0.01%	 (18) 20 	 0.01%	 (15) 0.00 0.0 0.26 0.613
Anxiety	disorder 151 	 0.10%	 (120) 98 	 0.07%	 (81) 0.03 -30.0 7.35	 0.007
Other	disorderse 212 	 0.15%	 (185) 114 	 0.08%	 (99) 0.07 -46.7 25.57 <0.001
aThe PA-exemption period was the 12 months between July 1, 2005, and June 30, 2006.
bThe post-PA exemption period was the 12 months between January 1, 2007, and December 31, 2007.
cCalculated by comparing the percentage of beneficiaries with at least 1 hospitalization in each study period.
dTotal number of beneficiaries who had at least 1 mental health hospitalization for depression, schizophrenia, bipolar disorder, personality disorder, anxiety disorder, or 
other disorder. 
eOther mental health disorders are specified by the ICD-9-CM codes in Table 1.
ICD-9-CM = International Classification of Diseases, Ninth Revision, Clinical Modification; PA = prior authorization.
TABLE 6 Incidence of Mental Health Inpatient Hospitalization by Subtype Stratified by Study Period
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Limitations
Foremost	 among	 the	 limitations	 of	 this	 study,	 we	 did	 not	
include	 a	 comparison	 group	 from	 another	 state,	 but	 rather	
used	a	pre	and	post	design.	As	a	result,	we	cannot	differenti-
ate	the	effect	of	extraneous	changes	in	the	marketplace	from	
the	effect	of	rescission	of	the	PA	exemption	for	SPMI.	However,	
apparent	 differences	 between	 the	population	 covered	 in	 the	
state	of	Vermont’s	Medicaid	program	and	other	state	Medicaid	
programs	would	make	selection	of	a	valid	comparison	group	
problematic	even	if	one	were	available.
Second,	our	study	is	a	real-world	analysis	of	a	managed	care	
policy	change,	and	we	do	not	know	the	proportion	of	the	study	
cohorts	 that	was	affected	by	 the	PA	exemption.	We	do	know	
that	the	proportion	affected	by	the	exemption	was	greater	than	
50%	of	the	cohort	samples	by	age	alone.	
Third,	 our	 analyses	 were	 restricted	 to	 the	 costs	 paid	 to	
pharmacies	 by	 the	 OVHA	 as	 recorded	 in	 pharmacy	 claims	
databases.	We	were	unable	to	account	for	manufacturer	rebates	
that	have	been	negotiated	by	OVHA,	and	 thus	 the	 true	costs	
to	 the	 Medicaid	 program	 may	 be	 overstated.	 In	 addition	 to	
federal	 rebates,	 Vermont	 participates	 in	 a	multistate	 pool	 for	
supplemental	 rebates	 with	 Michigan,	 Alaska,	 Nevada,	 New	
Hampshire,	 Hawaii,	 and	 Minnesota.12	 Drug	 manufacturer	
rebates	are	significant	 in	Medicaid	pharmacy	programs,27	but	
we	have	no	reason	to	believe	that	rebate	revenues	as	a	propor-
tion	of	total	spending	for	mental	health	drugs	would	have	dif-
fered	between	the	2	time	periods	in	the	present	study.	Although	
not	broken	out	by	drug	class,	the	state	of	Vermont	reported	that	
federal	rebates	were	about	27.1%	of	total	pharmacy	spending	in	
the	state’s	fiscal	year	2008,	plus	an	additional	4.7%	in	supple-
mental	rebates.28
Fourth,	 we	 are	 unable	 to	 ascertain	 the	 effect	 of	 “grandfa-
thering”	on	costs	and	utilization.	Prior	to	rescission	of	the	PA	 
exemption,	behavioral	health	medication	users	were	grandfa-
thered	to	prevent	“destabilization.”14	New	users	and	beneficia-
ries	who	had	lapses	in	treatment	greater	than	4	months	became	
subject	 to	 the	 PDL	 upon	 implementation	 of	 the	 rescission.14 
Our	 study	 was	 designed	 to	 mitigate	 the	 effects	 of	 grandfa-
thered	 users	 of	 behavioral	 health	 medications	 by	 employing	
a	 6-month	 “wash-out”	 period.	 Published	 data	 indicate	 that	
Vermont	 Medicaid	 PAs	 for	 nonpreferred	 behavioral	 health	
medications	 decreased	 by	 approximately	 54%	 from	 January	
2006	 to	 November	 2007.14	 This	 decrease	 may	 have	 resulted	
from	greater	adherence	to	the	PDL,	although	an	analysis	of	this	
association	is	beyond	the	scope	of	the	present	study.
Fifth,	 because	we	 did	 not	 have	 a	 comparison	 group	 from	
another	 state,	we	 could	not	 ascertain	 the	 effects	 of	 increased	
awareness	 and	 attention	 to	 the	 relationship	 between	 anti-
psychotic	 use	 and	 a	 higher	 prevalence	 of	 other	 disorders	
such	 as	 metabolic	 syndrome.29-31	 This	 syndrome	 is	 often	 
mental	health	drugs.	Hospitalizations	decreased	by	almost	one-
half	in	the	year	after	elimination	of	the	exemption	(2007).	More	
research	may	help	determine	if	treatment	was	shifted	to	other	
areas,	 such	as	outpatient	clinics,	 and	 to	our	knowledge	 there	
were	 no	 other	 initiatives	 by	 OVHA	 targeting	 mental	 health	
inpatient	hospitalizations.	Research	by	Shern	et	al.	(2008)	sug-
gested	that	mental	health	costs	shifted	from	health	care	centers	
to	private	care	 through	family	and	friends	after	 the	 introduc-
tion	of	Medicaid	managed	care.16	In	that	study,	although	costs	
to	the	Florida	Medicaid	system	did	decrease	in	the	presence	of	
managed	care,	there	were	no	differences	in	societal	costs.	It	is	
plausible	 that	 the	 decrease	 in	 inpatient	 hospitalizations	 seen	
in	this	study	resulted	in	subsequent	increases	in	care	in	other	
health	care	sectors.
Kaskie	 et	 al.	 (2006)	 compared	 2	 capitated	 models	 of	
Medicaid	mental	 health	 service	 delivery	with	 traditional	 fee-
for-service	Medicaid	 among	 enrollees	 aged	 65	 years	 or	 older	
in	Colorado.17	Although	our	 study	population	differed	by	 the	
exclusion	 of	 Medicare-eligible	 enrollees,	 Kaskie	 et	 al.	 also	
found	that	the	introduction	of	behavioral	health	managed	care	
to	a	Medicaid	population	 reduced	expenditures	while	having	
mixed	results	on	rates	of	utilization.	Authors	of	several	studies	
have	noted	that	introduction	of	behavioral	health	managed	care	
was	 associated	with	 reduced	 utilization	 of	 inpatient	 care.18-20 
However,	Burns	et	al.	(1999)	noted	that	utilization	of	intensive	
outpatient	services	increased,	while	Cook	et	al.	(2004)	did	not	
observe	any	change	in	outpatient	service	utilization.18,20	A	mul-
tisite	study	by	Leff	et	al.	(2005)	concluded	that	enrolling	high-
use	Medicaid	beneficiaries	in	behavioral	health	managed	care	
programs	(e.g.,	behavioral	health	“carve-outs”)	did	not	seem	to	
pose	 any	 short-term,	 large-scale	 negative	 consequences,	 such	
as	an	 increase	 in	 the	utilization	of	 intensive	 inpatient	mental	
health	services.21
Research	 by	 Soumerai	 et	 al.	 indicated	 that	 managed	 care	
restrictions	 could	 have	 a	 negative	 impact	 on	 Medicaid	 sub-
populations.22-26	 A	much-referenced	 study	 by	 Soumerai	 et	 al.	
(1994)	found	reductions	in	the	use	of	behavioral	health	medi-
cations	and	increased	use	of	mental	health	services	following	
the	 implementation	 of	 a	 3-prescription	 monthly	 payment	
limit	 on	psychotropic	 drugs	 and	 acute	mental	 health	 care	 in	
noninstitutionalized	beneficiaries	with	 acute	 schizophrenia.23 
A	more	recent	(2008)	analysis	concluded	that	the	initiation	of	
PA	for	nonpreferred	antipsychotics	in	West	Virginia	and	Texas	
decreased	the	market	share	of	these	agents	by	13.9%	and	2.6%	
respectively	after	2	years	but	was	not	associated	with	signifi-
cant	 reduction	 in	pharmacy	 reimbursements	 in	either	 state.24 
The	 authors	 noted	 that	 the	 economic	 value	 of	 supplemental	
rebates	associated	with	the	PDL	and	not	reported	in	available	
pharmacy	claims	could	not	be	evaluated.
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Authorscharacterized	 by	 obesity,	 hypertension,	 dyslipidemia,	 hype-
ruricemia,	 and	 diabetes,29	 and	 people	with	 this	 constellation	
of	 risk	 factors	 have	 a	 higher	 risk	 for	 cardiovascular	 and/or	
all-cause	mortality.31	 Therefore,	 patients	 taking	 antipsychotic	
medications	 might	 have	 higher	 overall	 drug	 costs	 than	 the	
rest	of	the	Medicaid	population	due	to	this	association.	In	fact,	
a	 cross-sectional	 observational	 study	 of	 adult	 Medicaid	 ben-
eficiaries	found	that	the	presence	of	any	psychiatric	diagnosis	
significantly	 increased	 total	 health	 care	 costs	 by	 over	 200%	
($3,121	per	year	to	$6,995	per	year).32	Heightened	awareness	of	
the	metabolic	syndrome	may	have	led	to	a	reduction	in	the	use	
of	these	medications	independent	of	the	phase-out	of	the	SPMI	
exemption.	Recent	research	has	added	further	confirmation	of	
this	association.32 
Sixth,	we	did	not	explore	 the	 reasons	 for	 the	 reduction	 in	
average	drug	cost	per	pharmacy	claim	for	the	3	mental	health	
drug	classes	combined,	and	for	the	antidepressants	in	particu-
lar,	 in	 the	period	after	elimination	of	 the	PA	exemption.	One	
obvious	reason	is	greater	adherence	to	the	PDL	including	the	
use	 of	 more	 first-line	 therapy	 including	 generic	 antidepres-
sants	such	as	citalopram,	paroxetine,	and	sertraline	(which	first	
became	available	by	generic	name	in	June	2006).	
■■  Conclusion
Many	 states	 such	 as	Vermont	have	 introduced	managed	 care	
initiatives	 in	 their	 publicly	 funded	 health	 care	 programs	 in	
an	 attempt	 to	 maintain	 quality	 and	 restrain	 cost	 increases.	
The	 exemption	of	 behavioral	 health	medications	 from	PA	 for	
Medicaid	beneficiaries	with	SPMI	was	implemented	in	Vermont	
in	 response	 to	criticism	about	 the	possible	adverse	effects	on	
a	“vulnerable”	population.	Phase-out	of	the	PA	exemption	was	
completed	in	June	2006,	but	current	users	of	behavioral	health	
medications	 continued	 to	be	 “grandfathered”	until	 a	 lapse	 in	
drug	 therapy	of	 4	months	 or	 longer	 occurred.	Therefore,	 the	
phase-out	 of	 the	 PA	 exemption	 provided	 an	 opportunity	 to	
analyze	 the	 effect	 of	 behavioral	 health	managed	 care	 in	 this	
Medicaid	 population.	 The	 growth	 of	 PMPM	 cost	 for	 behav-
ioral	health	medications,	which	represented	21%-23%	of	total	
pharmaceutical	costs,	was	small	compared	with	the	increase	in	
PMPM	costs	for	nonbehavioral	health	medications.	Secondary	
analyses	of	2	quality	measures,	the	percentage	of	beneficiaries	
who	were	hospitalized	with	mental	health	diagnoses	and	high-	
dose	 prescribing	 of	 antipsychotics,	 declined	 after	 removal	 of	
the	PA	exemption.	Despite	 the	PA	 requirement,	utilization	of	
behavioral	 health	 medications	 PMPM	 remained	 stable,	 and	
there	was	 a	 decrease	 in	 the	 average	 prescription	 cost	 for	 the	
behavioral	health	medications,	particularly	antidepressants.
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